Cargando…
Pan-cancer deconvolution of tumour composition using DNA methylation
The nature and extent of immune cell infiltration into solid tumours are key determinants of therapeutic response. Here, using a DNA methylation-based approach to tumour cell fraction deconvolution, we report the integrated analysis of tumour composition and genomics across a wide spectrum of solid...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6089972/ https://www.ncbi.nlm.nih.gov/pubmed/30104673 http://dx.doi.org/10.1038/s41467-018-05570-1 |
_version_ | 1783347111962607616 |
---|---|
author | Chakravarthy, Ankur Furness, Andrew Joshi, Kroopa Ghorani, Ehsan Ford, Kirsty Ward, Matthew J. King, Emma V. Lechner, Matt Marafioti, Teresa Quezada, Sergio A. Thomas, Gareth J. Feber, Andrew Fenton, Tim R. |
author_facet | Chakravarthy, Ankur Furness, Andrew Joshi, Kroopa Ghorani, Ehsan Ford, Kirsty Ward, Matthew J. King, Emma V. Lechner, Matt Marafioti, Teresa Quezada, Sergio A. Thomas, Gareth J. Feber, Andrew Fenton, Tim R. |
author_sort | Chakravarthy, Ankur |
collection | PubMed |
description | The nature and extent of immune cell infiltration into solid tumours are key determinants of therapeutic response. Here, using a DNA methylation-based approach to tumour cell fraction deconvolution, we report the integrated analysis of tumour composition and genomics across a wide spectrum of solid cancers. Initially studying head and neck squamous cell carcinoma, we identify two distinct tumour subgroups: ‘immune hot’ and ‘immune cold’, which display differing prognosis, mutation burden, cytokine signalling, cytolytic activity and oncogenic driver events. We demonstrate the existence of such tumour subgroups pan-cancer, link clonal-neoantigen burden to cytotoxic T-lymphocyte infiltration, and show that transcriptional signatures of hot tumours are selectively engaged in immunotherapy responders. We also find that treatment-naive hot tumours are markedly enriched for known immune-resistance genomic alterations, potentially explaining the heterogeneity of immunotherapy response and prognosis seen within this group. Finally, we define a catalogue of mediators of active antitumour immunity, deriving candidate biomarkers and potential targets for precision immunotherapy. |
format | Online Article Text |
id | pubmed-6089972 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-60899722018-08-15 Pan-cancer deconvolution of tumour composition using DNA methylation Chakravarthy, Ankur Furness, Andrew Joshi, Kroopa Ghorani, Ehsan Ford, Kirsty Ward, Matthew J. King, Emma V. Lechner, Matt Marafioti, Teresa Quezada, Sergio A. Thomas, Gareth J. Feber, Andrew Fenton, Tim R. Nat Commun Article The nature and extent of immune cell infiltration into solid tumours are key determinants of therapeutic response. Here, using a DNA methylation-based approach to tumour cell fraction deconvolution, we report the integrated analysis of tumour composition and genomics across a wide spectrum of solid cancers. Initially studying head and neck squamous cell carcinoma, we identify two distinct tumour subgroups: ‘immune hot’ and ‘immune cold’, which display differing prognosis, mutation burden, cytokine signalling, cytolytic activity and oncogenic driver events. We demonstrate the existence of such tumour subgroups pan-cancer, link clonal-neoantigen burden to cytotoxic T-lymphocyte infiltration, and show that transcriptional signatures of hot tumours are selectively engaged in immunotherapy responders. We also find that treatment-naive hot tumours are markedly enriched for known immune-resistance genomic alterations, potentially explaining the heterogeneity of immunotherapy response and prognosis seen within this group. Finally, we define a catalogue of mediators of active antitumour immunity, deriving candidate biomarkers and potential targets for precision immunotherapy. Nature Publishing Group UK 2018-08-13 /pmc/articles/PMC6089972/ /pubmed/30104673 http://dx.doi.org/10.1038/s41467-018-05570-1 Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Chakravarthy, Ankur Furness, Andrew Joshi, Kroopa Ghorani, Ehsan Ford, Kirsty Ward, Matthew J. King, Emma V. Lechner, Matt Marafioti, Teresa Quezada, Sergio A. Thomas, Gareth J. Feber, Andrew Fenton, Tim R. Pan-cancer deconvolution of tumour composition using DNA methylation |
title | Pan-cancer deconvolution of tumour composition using DNA methylation |
title_full | Pan-cancer deconvolution of tumour composition using DNA methylation |
title_fullStr | Pan-cancer deconvolution of tumour composition using DNA methylation |
title_full_unstemmed | Pan-cancer deconvolution of tumour composition using DNA methylation |
title_short | Pan-cancer deconvolution of tumour composition using DNA methylation |
title_sort | pan-cancer deconvolution of tumour composition using dna methylation |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6089972/ https://www.ncbi.nlm.nih.gov/pubmed/30104673 http://dx.doi.org/10.1038/s41467-018-05570-1 |
work_keys_str_mv | AT chakravarthyankur pancancerdeconvolutionoftumourcompositionusingdnamethylation AT furnessandrew pancancerdeconvolutionoftumourcompositionusingdnamethylation AT joshikroopa pancancerdeconvolutionoftumourcompositionusingdnamethylation AT ghoraniehsan pancancerdeconvolutionoftumourcompositionusingdnamethylation AT fordkirsty pancancerdeconvolutionoftumourcompositionusingdnamethylation AT wardmatthewj pancancerdeconvolutionoftumourcompositionusingdnamethylation AT kingemmav pancancerdeconvolutionoftumourcompositionusingdnamethylation AT lechnermatt pancancerdeconvolutionoftumourcompositionusingdnamethylation AT marafiotiteresa pancancerdeconvolutionoftumourcompositionusingdnamethylation AT quezadasergioa pancancerdeconvolutionoftumourcompositionusingdnamethylation AT thomasgarethj pancancerdeconvolutionoftumourcompositionusingdnamethylation AT feberandrew pancancerdeconvolutionoftumourcompositionusingdnamethylation AT fentontimr pancancerdeconvolutionoftumourcompositionusingdnamethylation |